We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

DRG International, Inc.

DRG International, a global innovator of high-quality medical diagnostics and equipment, provides the medical and res... read more Featured Products: More products

Download Mobile App




Systematic Serological Screening Programme Used for Strongyloidiasis

By LabMedica International staff writers
Posted on 13 Nov 2019
Print article
Image: Strongyloides stercoralis adult. The parasitic female lives threaded into the mucosal epithelium of the human small intestine (Photo courtesy of UVM Ecological Parasitology).
Image: Strongyloides stercoralis adult. The parasitic female lives threaded into the mucosal epithelium of the human small intestine (Photo courtesy of UVM Ecological Parasitology).
Strongyloidiasis is a soil-transmitted helminth infection caused by the nematode Strongyloides stercoralis and is endemic mainly in tropical and subtropical regions, but also in temperate regions.

This round worm infection is widely extended all over the world and it is estimated that at least 370 million individuals are infected worldwide, with a high degree of endemic burden in the tropical zones, especially Southeast Asia, Sub-Saharan Africa, and Latin America. As strongyloidiasis persists for life, it can cause serious morbidity or death long after an immigrant resettles in a new country.

Scientists at the Hospital de la Cruz Roja (Gijón, Spain) and their colleagues performed a prospective screening programme for strongyloidiasis between 2009 and 2014 for all immigrant patients attending the Tropical Medicine Unit. The patients were classified into seven groups according to their geographical area of origin (Central Africa, East Africa, West Africa, North Africa, Mexico and Central America, South America, and South Asia), following the US Centers for Disease Control and Prevention (CDC, Atlanta, GA, USA) criteria.

Three formalin-ether concentrated stool samples and an enzyme-linked immunosorbent assay (ELISA) for anti-S. stercoralis antibodies were used as the screening tools. The qualitative detection of IgG antibodies to S. stercoralis was done using an ELISA (DRG Diagnostics, Marburg, Germany) with microwells coated with Strongyloides antigen. A patient was considered as positive if at least one of the diagnostic tests used for screening (stool samples or/and ELISA) was positive. An eosinophil blood count was performed for all patients. Eosinophilia was defined as >500 eosinophils/mm3.

The team reported that of 659 patients screened, 79 (12%) were positive for S. stercoralis regardless of the diagnostic method used. The prevalence of infection was 42.9% in East African patients, 16.3% in Central African patients, 10.9% in those from South America, and 10% in the case of West Africa. Univariate analysis showed that infection by S. stercoralis was significantly more frequent in patients from Central Africa, and East Africa. Seventy-nine patients had a positive serological test for S. stercoralis; microscopic visualization of larvae of S. stercoralis by formalin-ether concentration of feces was positive for only four of them.

The authors recommended that immigrant patients from developing countries be routinely screened for S. stercoralis, especially those from East Africa. Due to the low sensitivity of stool examination for ova and parasites arising from low larval burden and intermittent shedding in the stool, serological testing is the diagnostic method of choice for screening in immigrant populations. The study was published in the November, 2019 issue of the International Journal of Infectious Diseases.

Related Links:
Hospital de la Cruz Roja
US Centers for Disease Control and Prevention
DRG Diagnostics


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.